Liminatus Pharma, Inc. financial data

Symbol
LIMN, LIMNW on Nasdaq
Location
La Palma, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -78% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27,064,633 shares
Common Stock, Shares, Outstanding 27,064,633 shares
Common Stock, Value, Issued $2,706 USD
Weighted Average Number of Shares Outstanding, Basic 27,007,568 shares 54%
Weighted Average Number of Shares Outstanding, Diluted 27,007,568 shares 54%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $701,170 USD 277%
Operating Income (Loss) $701,170 USD -29%
Nonoperating Income (Expense) $1,122,181 USD -1827%
Net Income (Loss) Attributable to Parent $1,823,351 USD -203%
Earnings Per Share, Basic -0.07 USD/shares -133%
Earnings Per Share, Diluted -0.07 USD/shares -133%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $1,203,370 USD
Property, Plant and Equipment, Net $12,764 USD
Assets $1,342,409 USD
Liabilities, Current $2,864,593 USD
Liabilities $2,988,172 USD
Retained Earnings (Accumulated Deficit) $30,702,806 USD
Stockholders' Equity Attributable to Parent $1,645,763 USD 91%
Liabilities and Equity $1,342,409 USD

Popular Metrics

Label TTM Value / Value Unit Change %
Common Stock, Shares Authorized 500,000,000 shares
Common Stock, Shares, Issued 27,064,633 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1,000,000 shares
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $29,054,337 USD
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares